Table 2 Treatment course among patients dying of uncontrolled capillary leak phenotype (CLP).

From: Capillary leak phenotype as a major cause of death in patients with POEMS syndrome

  1. Bold line demarcates the onset of CLP from POEMS syndrome diagnosis of 5 years.
  2. ASCT autologous stem cell transplant, Bev bevacizumab, C cyclophosphamide, CP cyclophosphamide and prednisone, D dexamethasone, Dara daratumumab, DRd daratumumab, lenalidomide (Revlimid), dexamethasone, Id ixazomib, dexamethasone, IRD ixazomib, lenalidomide, dexamethasone, KCd carfilzomib, cyclophosphamide, dexamethasone, MP melphalan and prednisone, P prednisone, Rad Radiation, Rd lenalidomide and dexamethasone, TP thalidomide and prednisone, Unk unknown, V bortezomib, VCd cyclophosphamide, bortezomib, dexamethasone, VR bortezomib and lenalidomide.
Back to article page